Innolife Pharma

With the aging demographic, chronic pain is becoming a larger and larger international epidemic. Innolife Pharma Inc. is positioned to be the leading service provider in this niche segment – with a licensing business model that is designed to provide excellent operating margins and tremendous growth for many years to come. Our totally proprietary therapy and drug free approach to managing chronic pain provides investors with an innovative, industry-dominating company and a way to build substantial wealth over time.

“…Pain has emerged as a devastating public health problem. According to the American Chronic Pain Association, pain is the No. 1 cause of adult disability in the U.S. At least one out of six people live with chronic pain.”
(WebMD Jan 2007)



Clinic greeting area	Patient candidate testing

Innolife Pharma Inc. Announces The Launching Of A New And Improved Website
May 28, 7:30 am ET

MARKHAM, ON -- (MARKET WIRE)--May 28, 2008 – Innolife Pharma, Inc. (Other OTC:INNP.PK <http://innp.pk/> - News) is pleased to announce that they have unveiled their new website. This new look should give investors and potential clients a much more comfortable feeling with regards to what INNP is trying to accomplish in their future endeavors.

About Innolife Pharma Inc.
Innolife Pharma Inc. (PINKSHEETS: INNP) is a small publicly traded specialty multi-discipline medical group focusing on licensing the Natural Pain Relief Center all-natural proprietary breakthrough in the treatment of chronic pain.

FORWARD-LOOKING STATEMENTS:
This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company.

Contact:
Innolife Pharma, Inc.
(905) 943-4938
info@innolifepharma.com
www.innolifepharma.com

Innolife Pharma Inc. acquires rights to breakthrough in non-narcotic chronic pain treatment
Relief soon to be widely available for chronic pain sufferers.
May 20, 7:30 am ET

MARKHAM, ON -- (MARKET WIRE)--May 20, 2008 – Innolife Pharma, Inc. (Other
OTC:INNP.PK - News) is pleased to announce that it has acquired North American licensing rights to the Natural Pain Relief Center non-narcotic proprietary breakthrough in the treatment of chronic pain.

Today, one in five Americans suffer with chronic pain (~ 60 million adults) spending
approximately $120 Billion a year and the aging baby boomers have reported in surveys more aches and pains than any previous generation.

New Medical Finding with Brain Scans and Functional MRI's
Modern Brain Imaging has revealed that most chronic pain is the result of the brain's inability to turn off pain messages from the body. In chronic pain the brain simply is not producing and releasing enough natural pain killers (such as endorphins) to stop the person's suffering. These new medical findings show that chronic pain sufferers from headaches, migraines, fibromyalgia, back pain, sciatica, arthritis or a combination of all of them, are caused by a low level of Natural
Pain Killer's (such as Endorphins and others) in the brain, as compared to people without chronic pain.

Over three years of in-clinic testing showed that this breakthrough all-natural program relieved significant chronic pain in 8 out of 10 people and with sustainable results. This non-narcotic, combination treatment has been receiving accolades from chronic pain sufferers with major improvement in mood and energy and dramatic decreases in pain levels, allowing a return to normal life function.

Innolife Pharma Inc. has an aggressive growth plan in place with a projected target of 95 licensed clinics in 3 years with projected top line annual revenue in excess of $30 million and a projected bottom line profit of over $12 million annually (40+%).

With the aging demographic, chronic pain is becoming a larger and larger international epidemic. Innolife Pharma Inc. is positioned to be the leading service provider in this segment – with a business model that is designed to provide excellent operating margins and tremendous growth for many years to come.

Innolife Pharma Inc. Provides Initial Update on Negotiations for Significant Product Joint Venture

MARKHAM, ON--(MARKET WIRE)--May 12, 2008 – Innolife Pharma, Inc. (Other OTC:INNP.PK - News) has been in discussion over the previous eight months regarding the formation of a joint venture partnership. INNP has reached a point in these negotiations where final written terms have been submitted on all key issues which could lead to the Company's very first product acquisition. It should be noted that this process evolved methodically over this extended period due to the successful, long term history of the product involved, and the well-established reputation of its founding corporation.

Management anticipates additional forthcoming news and progress updates on the closing of this transaction that can complete great strides in two specific areas. One is the awarding of valuable rights to Innolife Pharma of an industry leading product. This established brand known for innovation and consistency over more than two decades can be launched in a brand new target market for the first time representing the largest market of this type on a global scale. Secondly, but of equal importance, is the solidifying of a joint venture with a partner of great quality and experience. The intention is to unite the market access and distribution capabilities of INNP with the knowledge, leadership, and existing contacts of our potential joint venture partner.

INNP will continue to reveal details of our aggressive strategy geared towards long term growth as they become available. We are confident that a partnership will emerge and start to bring in revenue in the near term based on the high level of negotiations reached with an industry leader in the information technology field. The Company believes that the size of our target market is potentially in excess of US$20 Billion. Updates will also be available on the Company's official corporate web site at www.innolifepharma.com. Please bear with us as the site is still under development, but will be officially launched upon finalization of our partnership and product acquisition.